|
|
|
|
Дата |
|---|
| 03.12.2025 |
| 02.12.2025 |
| 01.12.2025 |
| 28.11.2025 |
| 26.11.2025 |
| 25.11.2025 |
| 24.11.2025 |
| 21.11.2025 |
| 20.11.2025 |
| 19.11.2025 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
|---|---|---|---|---|---|---|---|
|
11.75
|
11.92
|
10.43
|
10.36
|
12.0873
|
11.93
|
|
|
6 274 213.45
|
7 838.00
|
|
10.01
|
10.32
|
9.50
|
9.18
|
9.77
|
9.26
|
|
|
1 941 601.02
|
3 718.00
|
|
9.30
|
10.77
|
9.95
|
9.28
|
10.1031
|
9.52
|
|
|
1 972 489.06
|
4 217.00
|
|
9.75
|
10.80
|
9.87
|
9.805
|
10.44
|
9.98
|
|
|
1 346 385.00
|
2 869.00
|
|
9.32
|
10.00
|
9.43
|
9.2838
|
9.705
|
9.67
|
|
|
1 578 873.66
|
3 190.00
|
|
9.30
|
10.00
|
9.53
|
9.295
|
9.695
|
9.37
|
|
|
856 305.39
|
2 200.00
|
|
9.30
|
10.00
|
9.53
|
9.30
|
9.68
|
9.50
|
|
|
1 319 322.49
|
2 933.00
|
|
8.98
|
10.00
|
9.43
|
8.82
|
9.60
|
9.37
|
|
|
2 336 830.69
|
3 636.00
|
|
9.28
|
9.60
|
11.00
|
9.42
|
11.23
|
9.43
|
|
|
1 113 630.43
|
2 650.00
|
|
10.46
|
16.00
|
9.90
|
9.75
|
10.66
|
10.46
|
|
|
1 797 293.69
|
2 668.00
|
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is the ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen that is in Phase III clinical trial for hyperphagia associated with Prader-Willi Syndrome, as well as in Phase II clinical trial for hyperphagia associated with acquired hypothalamic obesity resultant from treatment of craniopharyngioma, including surgery or radiation.
It also developing ARD-201, which is in Phase I clinical trial for the treatment of obesity. The company was incorporated in 2017 and is based in San Diego, California.
Показать все Скрыть